Myeloproliferative Neoplasms (MPN)

- CNL/atypical CML
  - IRB# 10262 Oral Ruxolitinib for CNL or atypical CML.

- Myelofibrosis
  - IRB# 16363 Phase 2 INC050465 plus Ruxolitinib
  - IRB# 15836 Dual Syk/Jak inhibitor for myelofibrosis with JAK2 mutation

- Systemic Mastocytosis
  - IRB# 17899 Study Coming Soon

- IRB# 15977 Non Treatment National MDS Study (ECOG/ACRIN)

http://www.ohsu.edu/research/rda/so/knight.php